报价延迟最少15分钟:2026/04/17 17:20 EDT
盘后时段
|
||||
|
5.34 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.34
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.20/-1.20
|
|
企业价值
125.35M
|
| 资产负债 |
|
每股账面净值
-0.70
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
39.99K
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developingdrug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma. |
